---
schema_version: "secwatch.filing_event.v1"
accession: "0001649094-26-000041"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2026-08-05T20:07:51+00:00"
generated_at: "2026-08-05T20:11:20.304312+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte Q2 net loss $284M; VAX-31 OPUS-1 topline data expected Q4 2026

## Summary
- Net loss of $284.3M in Q2 2026 vs $166.6M in Q2 2025; R&D expenses rose to $267.9M.
- Cash, equivalents and investments $2.5B as of June 30, 2026, up from $2.44B at year-end 2025.
- VAX-31 adult Phase 3 OPUS-1 noninferiority trial fully enrolled; topline data due Q4 2026.
- VAX-31 infant Phase 2 dose-finding study data expected by end of H1 2027.
- Phase 1 study of VAX-A1 (Group A Strep) initiated; topline data expected H2 2027.

## SEC filing metadata
- accession: 0001649094-26-000041
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2026-08-05T20:07:51+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/0001649094-26-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/pcvx-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001649094-26-000041
- JSON: https://secwatch.observer/filing/0001649094-26-000041.json
- Plain text: https://secwatch.observer/filing/0001649094-26-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.